|
| Study | Design | Location | No. of patients | Mean age | Men | Therapy | Stage | Definition of statin use | Number of patients with statin use | Follow-up durations | Variables controlled | Outcomes reported |
|
| | | | | years | % | | | | | months | | |
|
| Samaras 2010 | R | Switzerland | 145 | 57.3 | 56.6 | R-CHOP as first line therapy | I–IV | Concurrent use of statin as evidenced by medical chart | 21 | 24 | Age, sex, stage, and IPI | OS and PFS |
|
| Ennishi 2010 | R | Japan | 256 | 64.5 | 55.9 | R-CHOP as first line therapy | I–IV | Concurrent use of statin for at least two months as evidenced by medical chart | 35 | 32 | Age, sex, cholesterol profile, and IPI | OS and PFS |
|
| Nowakowski 2010 | P | The US | 228 | NR | 56 | R-CHOP or R-CHOP–like chemotherapy | I–IV | Concurrent use of statin as evidenced by medical chart | 39 | 47 | Age, sex, stage, and IPI | OS and PFS |
|
| Koo 2011 | R | Singapore | 213 | 59.1 | 50.7 | R-CHOP or R-CHOP–like chemotherapy | I–IV | Concurrent use of statin as evidenced by medical chart | 47 | 17 | Age, sex, stage, performance status, serum LDH and chemotherapy regimens | OS and PFS |
|
| Song 2015 | R | Korea | 409 | 61 | 57.2 | R-CHOP | I–IV | Concurrent use of statin as evidenced by medical chart | 146 | 39 | Age, sex, stage, and performance status | OS and PFS |
|
| Smyth 2020 | R | Canada | 4275 | 75 | 51 | NR | I–IV | Previous use of statin within 1 year before enrollment | 1607 | 12 | Age, sex, and income level | OS |
|
| Branvall 2021 | P | Sweden | 4130 | 69 | 57.2 | NR | I–IV | Previous use of satin before the enrollment | 873 | 25 | Age, sex, year of diagnosis, education, and concomitant medications | OS |
|
| Gouni 2021 | R | The US | 271 | NR | 49 | R-CHOP | III–IV | Concurrent use of statin as evidenced by medical chart | 79 | 77 | Age, sex, stage, and performance status | OS and PFS |
|
